In order to further disseminate its proprietary barrier technology, on which the new concept “mucoprotection” is based, and as part of its continuous investment in its products´ reputation, Noventure has just participated in this year´s ESPGHAN Congress, held in Prague.
Pediatric gastroenterologists are a key target group for the recommendation and endorsement of new approaches to the management of GI conditions in children. A record number of such specialists (more than 6.500 delegates) from both European and non-European countries participated at the congress, and many of them approached Noventure´s stand to request information.
Our products intended for acute diarrhea (Tasectan and Xilaplus, already marketed), as well as our upcoming launch for infant colics, triggered a lot of interest and expectation among doctors.
As usual, representatives from some of Noventure´s preferred partners (this time Onko Kocsel, Lapidot, Valeant and Ferrer) took advantage of our booth to meet and greet there their own customers.
On top of all that, 2 new posters on 2 clinical trials with Tasectan in Turkey were presented.
In accordance with article 5 of the Spanish Law RDL1/2015, the information set out in the following sections is intended for healthcare professionals.
Access to this information and all use which may be made thereof or of these contents is exclusive responsibility of those who use them. Noventure will not be held liable for any illegal or improper use or for the manipulation of the contents and information included in these pages.